Intrinsiqs

Is Lyell Immunopharma, Inc. overvalued?

Lyell Immunopharma, Inc. (LYEL) — key valuation metrics and fundamentals.

No verdict
Price
$14.30
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$351.6M
Dividend yield
0.0%
Return on equity
-107.6%
Sector
Healthcare

See the full interactive analysis →

Fair value compares LYEL's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Nov 2026.